Table 1. Summary of The Results of In Vitro Susceptibility Testing of C. Pneumoniae.
|
Antibiotic |
MIC on first passage (µg/mL) |
MIC on second passage (µg/mL) |
|
|
|
|
|
Tetracycline |
0.05 |
0.05-4 |
|
Doxycycline |
0.05-0.5 |
0.125-0.5 |
|
Minocycline |
0.015 |
NA |
|
Erythromycin |
0.01-0.25 |
0.01-4.0 |
|
Azithromycin |
0.06-1.0 |
0.125-2.0 |
|
Clarithromycin |
0.004-0.25 |
0.004-2.0 |
|
Roxithromycin |
0.125-0.25 |
0.125 |
|
Ciprofloxacin |
0.25-4.0 |
0.25-8.0 |
|
Ofloxacin |
0.5-2.0 |
0.5-2.0 |
|
Levofloxacin |
0.25-1.0 |
0.25-1.0 |
|
Fleroxacin |
2.0-8.0 |
2.0-8.0 |
|
Temafloxacin |
0.125-4.0 |
0.125-40 |
|
Gatifloxacin |
0.06-0.25 |
0.06-0.25 |
|
Gemifloxacin |
0.06-0.25 |
0.125-0.25 |
|
Grepafloxacin |
0.06-0.5 |
0.03-0.5 |
|
Sparfloxacin |
0.06-0.5 |
0.06-0.25 |
|
Trovafloxacin |
0.5-1.0 |
0.5-1.0 |
|
Ampicillin |
>100 |
0.8-1.6 |
|
Penicillin |
>100 |
0.1-0.2 |
|
Sulfisoxazole |
>400 |
> 400 |
|
Sulfamethoxazole |
>500 |
NA |
NA = not available.
Figure 1: C. pneumoniae Interaction with Different Human Cell Types